遲發性運動障礙治療市場 - 按藥物（Deutetrabenazine、Valbenazine）、劑型（膠囊、片劑）、配銷通路（醫院藥房、藥房和零售藥房、線上藥房） - 全球預測（2024 - 2032）

2024年至2032年，全球遲發性運動障礙治療市場的複合年成長率將超過7.1%，原因是需要長期抗精神病藥物治療的慢性精神疾病的盛行率不斷增加，從而增加了遲發性運動障礙的發生率。神經精神病學研究的進步使人們更好地理解和認知了這種疾病，促進了更有針對性和更有效的治療方案的發展。

重點是開發新的藥物類別和配方，以更好地管理症狀並減少副作用。這將改善患者的治療效果並解決未滿足的醫療需求，以刺激市場擴張。藥物機制和給藥方法的不斷創新正在促進遲發性運動障礙治療市場的成長。舉個例子，梯瓦製藥公司宣佈在 2024 年初啟動一項新的 3 期臨床試驗，重點研究一種旨在減輕遲發性運動障礙症狀的新型化合物。該研究預計將深入了解該藥物的功效和安全性，並有可能為治療領域設定新標準。

整個遲發性運動障礙治療產業根據藥物、劑型、配銷通路和地區進行分類。

丁苯那嗪細分市場在預測期內將錄得值得稱讚的複合年成長率，這歸因於人們越來越認知到其有效解決治療抗藥性病例的潛力。重點在於最佳化治療結果、減少副作用，並為對傳統治療反應不佳的患者提供更好的治療選擇。醫療保健提供者和患者對丁苯那嗪優點的認知的提高對其採用產生了積極影響。此外，良好的臨床試驗結果和臨床指南的支持也有利於該細分市場的成長。

由於人們越來越青睞方便且患者友善的劑型，膠囊細分市場將在 2032 年獲得有前景的遲發性運動障礙治療市場佔有率。膠囊劑量準確且易於攝入，從而提高患者的依從性和對治療方案的依從性。此外，掩蓋令人不愉悅的味道和氣味的能力使膠囊成為患者更容易接受的選擇。隨著醫療保健提供者和患者尋求更易於管理和更有效的治療解決方案，膠囊細分市場的佔有率將會激增。

到 2032 年，歐洲遲發性運動障礙治療市場將呈現顯著的複合年成長率，因為人們對該疾病的認知不斷提高，診斷能力不斷提高，從而能夠更好地識別疾病。該地區先進的醫療基礎設施支持先進的治療方案，同時增加對神經病學研究的投資提高了治療的可用性。此外，歐洲人口老化和慢性病盛行率上升導致對有效 TD 管理的需求不斷成長。有利的醫療保健政策和報銷策略有助於獲得更新、更有效的治療方法，推動整個歐洲的市場成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 遲發性運動障礙盛行率上升
    • 提高對遲發性運動障礙的認知與教育
    • 研發活動數量不斷增加
    • 治療學不斷進步
  • 產業陷阱與挑戰
    • 治療費用高
    • 嚴格的法規核准
• 成長潛力分析
• 監管環境
• 管道分析
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀錶板

第 5 章：市場估計與預測：按藥品分類，2021 - 2032 年

• 主要趨勢
• 丁苯那嗪
• 纈苯那嗪
• 其他藥品

第 6 章：市場估計與預測：按劑型，2021 - 2032

• 主要趨勢
• 膠囊
• 平板電腦

第 7 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 藥局和零售藥局
• 網路藥局

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• H. Lundbeck A/S
• Luye Pharma Group
• Mitsubishi Tanabe Pharma Corporation
• Neurocrine Biosciences Inc.
• SteriMax Inc.
• SOM Biotech
• Teva Neuroscience, Inc.

Global Tardive Dyskinesia Therapeutics Market will showcase over 7.1% CAGR from 2024 to 2032, owing to the growing prevalence of chronic psychiatric conditions requiring long-term antipsychotic treatment, which increases the incidence of tardive dyskinesia. Advances in neuropsychiatric research have led to better understanding and recognition of the disorder, prompting the development of more targeted and effective therapeutic options.

There is focus on developing new drug classes and formulations that offer better management of symptoms and reduced side effects. This will improve patient outcomes and addresses unmet medical needs, stimulating market expansion. Continuous innovation in drug mechanisms and delivery methods is contributing to tardive dyskinesia therapeutics market growth. Quoting an instance, Teva Pharmaceuticals announced the initiation of a new Phase 3 clinical trial in early 2024, focusing on a novel compound aimed at reducing tardive dyskinesia symptoms. The study is expected to provide insights into the drug's efficacy and safety, potentially setting a new standard in the treatment landscape.

The overall tardive dyskinesia therapeutics industry is sorted based on drug, dosage form, distribution channel, and region.

The Deutetrabenazine segment will record a commendable CAGR during the forecast period, attributable to the growing recognition of its potential to address treatment-resistant cases effectively. There is emphasis on optimizing therapeutic outcomes, reducing side effects, and offering improved management options for patients who have not responded well to conventional treatments. Enhanced awareness among healthcare providers and patients about the advantages of deutetrabenazine positively influences its adoption. Additionally, favorable clinical trial results and support from clinical guidelines are favoring the segment growth.

The capsules segment will acquire a promising tardive dyskinesia therapeutics market share by 2032, owing to the increased preference for convenient and patient-friendly dosage forms. Capsules offer accurate dosing and ease of ingestion, which improves patient compliance and adherence to treatment regimens. Additionally, the ability to mask unpleasant tastes and odors makes capsules a more acceptable option for patients. As healthcare providers and patients seek more manageable and effective treatment solutions, the capsules segment share will surge.

Europe tardive dyskinesia therapeutics market will evince a notable CAGR through 2032, because of heightened awareness about the condition, and improved diagnostic capabilities leading to better disease identification. The region's progressive healthcare infrastructure supports advanced treatment options while increasing investments in neurology research enhance therapeutic availability. Furthermore, Europe's aging population and rising prevalence of chronic conditions contribute to the growing need for effective TD management. Favorable healthcare policies and reimbursement strategies facilitate access to newer and more effective therapies, driving market growth across Europe.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of tardive dyskinesia
    • 3.2.1.2 Increased awareness and education about tardive dyskinesia
    • 3.2.1.3 Growing number of research and development activities
    • 3.2.1.4 Increasing advancement in therapeutics
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Stringent regulatory approvals
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Deutetrabenazine
• 5.3 Valbenazine
• 5.4 Other drugs

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Capsules
• 6.3 Tablets

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Drug store & retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 The Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 H. Lundbeck A/S
• 9.2 Luye Pharma Group
• 9.3 Mitsubishi Tanabe Pharma Corporation
• 9.4 Neurocrine Biosciences Inc.
• 9.5 SteriMax Inc.
• 9.6 SOM Biotech
• 9.7 Teva Neuroscience, Inc.